Suppr超能文献

快速美罗培南/法硼巴坦 NP 试验检测肠杆菌科的药敏/耐药性。

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales.

机构信息

Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.

Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.

出版信息

J Antimicrob Chemother. 2023 Oct 3;78(10):2428-2434. doi: 10.1093/jac/dkad224.

Abstract

BACKGROUND

The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance determinants worldwide. Meropenem/vaborbactam was recently approved for clinical use and it has been indicated for treating several infections. Although relatively rare, meropenem/vaborbactam resistance has already been reported in Enterobacterales and its early detection could be a valuable tool for faster clinical decision-making.

OBJECTIVES

To develop a rapid test, namely the Rapid MEV NP, for the identification of meropenem/vaborbactam resistance in Enterobacterales.

METHODS

The Rapid MEV NP test is based on detection of glucose metabolization occurring upon bacterial growth in the presence of meropenem/vaborbactam at a concentration of 16/8 mg/L. Bacterial growth is detectable by a colour change of phenol red (from red to yellow) subsequent of the acidification of the medium upon bacterial growth. A total of 75 Enterobacterales isolates were randomly selected for evaluating the performance of the Rapid MEV NP test.

RESULTS

The test showed 97.2% sensitivity and 93.8% specificity when compared with the reference method. The results are obtained after 3 h of incubation at 35°C ± 2°C, which is a gain of time of at least 15 h (one day in practice) compared with currently used antimicrobial susceptibility testing including broth microdilution methods.

CONCLUSIONS

The Rapid MEV NP test, easy to perform and to interpret, showed remarkable performance while providing fast results, and is therefore suitable for implementation in routine clinical microbiology laboratories.

摘要

背景

如今,治疗碳青霉烯类耐药肠杆菌科(CRE)感染的选择方案极为有限,而新抗生素的研发速度跟不上全球碳青霉烯类耐药决定因素的指数级传播。美罗培南/法硼巴坦最近已被批准用于临床,且已被用于治疗多种感染。尽管相对罕见,但肠杆菌科已出现对美罗培南/法硼巴坦的耐药性,早期检测可能是更快临床决策的有价值工具。

目的

开发一种快速检测方法,即 Rapid MEV NP,用于鉴定肠杆菌科中的美罗培南/法硼巴坦耐药性。

方法

Rapid MEV NP 检测法基于在 16/8 mg/L 美罗培南/法硼巴坦浓度下,细菌生长时葡萄糖代谢的检测。细菌生长可通过酚红(从红色变为黄色)的颜色变化来检测,这是由于细菌生长导致培养基酸化。共随机选择 75 株肠杆菌科分离株用于评估 Rapid MEV NP 检测法的性能。

结果

与参考方法相比,该检测法的灵敏度为 97.2%,特异性为 93.8%。在 35°C±2°C 孵育 3 小时后即可获得结果,与目前包括肉汤微量稀释法在内的抗菌药物敏感性检测相比,至少节省了 15 小时(实际为一天)的时间。

结论

Rapid MEV NP 检测法易于操作和解释,具有显著的性能,同时提供快速结果,因此适合在常规临床微生物学实验室中实施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ab2/10702849/0bca77040351/dkad224f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验